RTB101 Well-tolerated, Crosses Blood-Brain Barrier in Therapeutic Quantities, According to Interim Results

RTB101 Well-tolerated, Crosses Blood-Brain Barrier in Therapeutic Quantities, According to Interim Results
RTB101, an investigational therapy being developed to treat Parkinson’s disease, is well-tolerated, can cross the blood-brain barrier, and reaches potentially therapeutic concentrations in cerebrospinal fluid (CSF), according to interim results of a Phase 1b/2a study. Developed by resTORbio, RTB101 is an orally-administered compound meant to induce autophagy in neuronal cells by inhibiting a protein called target of rapamycin complex 1 ... read more
Source: Parkinson’s News TodayPublished on 2020-02-20By Forest Ray, PhD